Biogen (BIIB) Asset Writedowns and Impairment (2009 - 2026)

Biogen's Asset Writedowns and Impairment history runs 11 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 34.25% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $61.2 million (up 53.0% YoY), while the FY2025 annual figure was $29.2 million, down 51.5% from the prior year.
• Asset Writedowns and Impairment was $4.8 million for Q1 2026 at Biogen, down from $52.9 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $275.0 million in Q1 2022 to a low of -$62.1 million in Q4 2023.
• Historically, Asset Writedowns and Impairment has averaged $69.5 million across 5 years, with a median of $19.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Asset Writedowns and Impairment surged 2210.92% in 2022, then sank 122.58% in 2023.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $275.0 million in 2022, then slumped by 122.58% to -$62.1 million in 2023, then surged by 120.13% to $12.5 million in 2024, then jumped by 323.2% to $52.9 million in 2025, then tumbled by 90.93% to $4.8 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $4.8 million (Q1 2026), $52.9 million (Q4 2025), and $3.5 million (Q2 2025), per Business Quant data.